US › Healthcare

Hyperfine Inc (HYPR)

US · Healthcare · Medical Devices

$0.77-0.18%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$3.9M

Revenue YoY

+44.8%

Net profit

$-9.3M

EPS

$-0.09

EPS estimate

$-0.09

Net margin

-238.2%

EPS came in at -0.09 against a street estimate of -0.09 — a beat of 0.0%.

Key statistics

Market cap

$85.0M

Forward P/E

0.0

P/B

2.32

Book value

$0.35

EPS (TTM)

$-0.37

52-week high

$2.22

52-week low

$0.78

50-day MA

$0.93

200-day MA

$1.17

Beta

1.41

Analyst view

Analysts rate Hyperfine Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $2.03.

Shareholding

Insiders

4.44%

Institutions

22.49%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.26%
Fosun International Ltd	1.64%
Catalio Capital Management, LP	1.24%
Geode Capital Management, LLC	0.90%
Alphabet Inc	0.85%
Renaissance Technologies Corp	0.69%
BlackRock Inc	0.54%
Vanguard Fiduciary Trust Co	0.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hyperfine Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.